Claudin-Targeted Drug Therapy
Zolbetuximab is the first and only FDA-approved drug that directly targets claudin proteins, specifically claudin-18.2 (CLDN18.2), for use in CLDN18.2-positive, HER2-negative advanced gastric and gastroesophageal junction adenocarcinomas. 1
FDA-Approved Agent
Zolbetuximab is a monoclonal antibody directed against CLDN18.2 that received FDA approval for first-line treatment when combined with fluoropyrimidine plus platinum chemotherapy 2, 3. The approval was based on Phase III trials (SPOTLIGHT and GLOW) demonstrating improved progression-free survival (HR 0.564) and overall survival (HR 0.716) compared to chemotherapy alone 4.
Patient Selection Criteria
- CLDN18.2 positivity threshold: Moderate to strong (2+/3+) membrane staining in ≥75% of tumor cells 1
- HER2-negative status is required 1
- Advanced or metastatic disease setting 1
Testing Requirements
The biomarker assessment must be performed on invasive adenocarcinoma tissue using immunohistochemistry 1. Key technical points:
- Both isoform-specific and pan-claudin-18 antibodies are acceptable
- Normal gastric epithelium serves as internal positive control (shows "dark chocolate" brown membranous staining)
- Precursor lesions (intestinal metaplasia, dysplasia) should NOT be scored
- Cases with 60-80% positivity require second pathologist review 1
Clinical Implementation Challenges
Real-world use of zolbetuximab presents practical difficulties 2:
- Cumbersome administration times with extended observation periods
- Short drug stability requiring immediate use
- Significant gastrointestinal toxicity, particularly nausea and vomiting during initial cycles
- Higher rates of neutropenia compared to chemotherapy alone 4
- Toxicity is notably worse in patients with intact stomachs (no prior gastrectomy)
- Requires aggressive antiemetic regimens 3
Investigational Agents
Multiple next-generation CLDN18.2-targeted therapies are in clinical development, showing promising early results 3, 5:
Antibody-Drug Conjugates (ADCs)
ADCs targeting CLDN18.2 have demonstrated greater antitumor activity than zolbetuximab-based regimens in single-arm studies 4. These agents combine the targeting specificity of anti-CLDN18.2 antibodies with cytotoxic payloads, potentially overcoming the limited single-agent response rates seen with zolbetuximab 3.
Bispecific Antibodies
Bispecific T-cell engagers (BiTEs) that simultaneously bind CLDN18.2 and T-cell receptors are under investigation 5, 6.
CAR-T Cell Therapy
Chimeric antigen receptor T-cells engineered to target CLDN18.2 are being explored, particularly for overcoming drug resistance mechanisms 5, 7, 6.
CLDN18.2 Expression Beyond Gastric Cancer
While zolbetuximab is approved only for gastric/GEJ adenocarcinomas, CLDN18.2 expression has been documented in other malignancies 3:
- Pancreatic adenocarcinoma
- Ovarian cancer
- Biliary tract cancers (though underrepresented in clinical trials) 6
Early basket trials are evaluating CLDN18.2-targeted therapies across these tumor types, though prevalence data and optimal cutoff thresholds remain inadequately defined for non-gastric cancers 6.
Critical Caveats
Expression Heterogeneity
- CLDN18.2 shows high intratumoral heterogeneity 1
- Expression can change with treatment 3
- Variability exists between primary and metastatic sites, though concordance is generally high 1
Biomarker Standardization Gap
Standardized definitions for CLDN18.2 positivity and high expression are urgently needed across tumor types 4. The 75% cutoff used for zolbetuximab approval may not be optimal for other CLDN18.2-targeted modalities or cancer types.
Tolerability Profile
Despite CLDN18.2 expression on normal gastric mucosa, these therapies have been generally tolerable in trials, but require aggressive supportive care, particularly antiemetics 3. The gastrointestinal toxicity reflects on-target effects on normal gastric epithelium.
Other Claudin Targets
While CLDN18.2 is the only claudin with an approved targeted therapy, research on other claudin family members is emerging. For example, saquinavir (an HIV protease inhibitor) has been shown to downregulate claudin-2 expression in lung adenocarcinoma through enhanced endocytosis and lysosomal degradation, potentially reversing chemoresistance 8. However, this remains investigational with no clinical approval for cancer treatment.